We speculate that ESR1 has diagnostic value in clinicopathological features and prognosis of patients with gastric cancer, and selective targeting of the estrogen receptor may be a new therapeutic tool to eliminate tumor growth and metastasis. This evidence concerns the gene ESR1 and gastric cancer.